BTK [p Tyr223] Antibody - BSA Free

Bruton's tyrosine kinase (BTK) takes part in B-cell ontogeny, differentiation, and signaling. A kinase member of the Tec family, it's signaling leads to cytoskeletal changes, as well as calcium, NF kappa B, and NFAT signaling. Defects in the gene cause X-linked agammaglobulinemia (XLA). Autophosphorylation can occur on Tyr-223 and Tyr-551. pY223 activates the protein that is inhibited by IBTK, and creates a docking site for SH2 domain proteins.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 5 applications: FLOW, ICC/IF, IF/IHC, PLA, WB.

Showing Publications 1 - 6 of 6.

Publications using NBP1-78295	Applications	Species
Rehman R, Miller M, Krishnamurthy SS et al. Met/HGFR triggers detrimental reactive microglia in TBI Cell reports 2022-12-27 [PMID: 36577378] (IF/IHC, WB, Mouse)	IF/IHC, WB	Mouse
Zhang J FLT3/FLT3L signaling modulates splenic dendritic cells maturation upon traumatic brain injury and is enhanced by ethanol intoxication Thesis 2023-01-01 (ICC/IF, Mouse) Details: 1:200 ICC/IF diltuion	ICC/IF	Mouse
FlUmann R, RehkAmper T, Nieper P Et al. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities Blood Cancer Discov 2021-01-15 [PMID: 33447829] (PLA, Mouse) Details: Citation using the HRP version of this antibody.	PLA	Mouse
Wang SP, Iwata S, Nakayamada S et al. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation Rheumatology (Oxford) 2015-02-26 [PMID: 25724205] (FLOW, Human) Details: BTK [p Tyr223] antibody used for FLOW on human CD19+ B cells in PBMCs alongwith rabbit IgG isotype control (see full text for detailed protocol).	FLOW	Human
Eda H, Santo L, Cirstea DD et al. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia 2014-02-12 [PMID: 24518207] (WB, Human)	WB	Human
Gleixner KV, Peter B, Blatt K, Suppan V et al. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V Haematologica 2013-03-28 [PMID: 23539538] (WB, Human)	WB	Human

Array NBP1-78295

• BTK Antibodies
• BTK ELISA Kits
• BTK Lysate
• BTK Proteins